LON:PRTC - PureTech Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 718.75
  • Forecasted Upside: 101.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 356
▲ +8 (2.30%)

This chart shows the closing price for PRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PureTech Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTC

Analyst Price Target is GBX 718.75
▲ +101.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PureTech Health in the last 3 months. The average price target is GBX 718.75, with a high forecast of GBX 930 and a low forecast of GBX 475. The average price target represents a 101.90% upside from the last price of GBX 356.

This chart shows the closing price for PRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in PureTech Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/24/2021Liberum CapitalReiterated RatingBuyGBX 540
5/27/2021Peel HuntReiterated RatingBuyGBX 930
5/27/2021Peel HuntReiterated RatingBuyGBX 930
4/15/2021Liberum CapitalReiterated RatingBuyGBX 550
1/19/2021Jefferies Financial GroupReiterated RatingBuyGBX 475
1/18/2021Liberum CapitalReiterated RatingBuyGBX 490
7/29/2020Liberum CapitalBoost Price TargetBuyGBX 450 ➝ GBX 490
7/8/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Liberum CapitalReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/16/2020Peel HuntReiterated RatingBuy
6/16/2020Liberum CapitalReiterated RatingBuy
6/9/2020Liberum CapitalReiterated RatingBuy
6/8/2020Peel HuntReiterated RatingBuy
6/2/2020Peel HuntReiterated RatingBuyGBX 480
6/2/2020Peel HuntReiterated RatingBuyGBX 480
5/28/2020Liberum CapitalReiterated RatingBuyGBX 450
5/26/2020Peel HuntReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/23/2020Liberum CapitalReiterated RatingBuy
4/23/2020Peel HuntReiterated RatingBuy
4/14/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/3/2020Peel HuntReiterated RatingBuy
2/25/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/23/2020Peel HuntReiterated RatingBuyGBX 480
1/23/2020Liberum CapitalReiterated RatingBuyGBX 420 ➝ GBX 450
1/23/2020Peel HuntReiterated RatingBuyGBX 480
1/16/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalLower Price TargetBuyGBX 450 ➝ GBX 420
1/10/2020Peel HuntReiterated RatingBuy
12/19/2019Peel HuntReiterated RatingBuyGBX 480
12/13/2019Peel HuntReiterated RatingBuy
12/9/2019Liberum CapitalReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/22/2019Peel HuntBoost Price TargetBuyGBX 380 ➝ GBX 460
11/18/2019Peel HuntReiterated RatingBuyGBX 380 ➝ GBX 460
11/15/2019Liberum CapitalReiterated RatingBuyGBX 347 ➝ GBX 300
11/4/2019Peel HuntReiterated RatingBuy
10/2/2019Peel HuntReiterated RatingBuyGBX 380
10/2/2019Peel HuntReiterated RatingBuyGBX 380
9/23/2019Peel HuntReiterated RatingBuy
9/9/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/27/2019Liberum CapitalBoost Price TargetBuyGBX 336 ➝ GBX 347
8/27/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/17/2019Liberum CapitalReiterated RatingBuy
7/17/2019Peel HuntReiterated RatingBuyGBX 344 ➝ GBX 380
7/11/2019Peel HuntReiterated RatingBuy
7/11/2019Liberum CapitalReiterated RatingBuy
7/5/2019Jefferies Financial GroupBoost Price TargetBuyGBX 280 ➝ GBX 340
7/3/2019Peel HuntReiterated RatingBuyGBX 344
7/2/2019Liberum CapitalBoost Price TargetBuyGBX 308 ➝ GBX 336
6/28/2019Peel HuntReiterated RatingBuyGBX 344
6/13/2019Liberum CapitalReiterated RatingBuy
6/13/2019Peel HuntReiterated RatingBuy
6/3/2019Liberum CapitalReiterated RatingBuy
6/3/2019Peel HuntReiterated RatingBuy
5/16/2019Liberum CapitalReiterated RatingBuy
5/13/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
4/24/2019Liberum CapitalReiterated RatingBuy
4/24/2019Peel HuntReiterated RatingBuy
4/17/2019Jefferies Financial GroupReiterated RatingBuyGBX 255
4/17/2019Peel HuntReiterated RatingBuy
4/15/2019Liberum CapitalReiterated RatingBuy
4/11/2019Peel HuntReiterated RatingBuyGBX 320 ➝ GBX 344
4/2/2019Peel HuntReiterated RatingBuy
3/18/2019Peel HuntReiterated RatingBuy
3/18/2019Liberum CapitalReiterated RatingBuy
3/7/2019Jefferies Financial GroupReiterated RatingBuyGBX 255
3/7/2019Peel HuntReiterated RatingBuyGBX 313 ➝ GBX 320
3/7/2019Liberum CapitalReiterated RatingBuy
2/14/2019Liberum CapitalReiterated RatingBuy
2/14/2019Peel HuntReiterated RatingBuy
1/31/2019Peel HuntReiterated RatingBuy
1/24/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
1/4/2019Jefferies Financial GroupBoost Price TargetBuyGBX 245 ➝ GBX 255
12/24/2018Peel HuntReiterated RatingBuy
12/18/2018Peel HuntReiterated RatingBuy
12/10/2018Liberum CapitalReiterated RatingBuy
12/6/2018Peel HuntReiterated RatingBuyGBX 313
11/27/2018Liberum CapitalReiterated RatingBuy
11/26/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/26/2018Liberum CapitalReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/11/2018Jefferies Financial GroupBoost Price TargetBuyGBX 245 ➝ GBX 255
9/11/2018Peel HuntReiterated RatingBuy
9/11/2018Liberum CapitalReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/9/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/26/2018Liberum CapitalReiterated RatingBuy
7/20/2018Peel HuntReiterated RatingBuy
7/20/2018Liberum CapitalReiterated RatingBuy
7/12/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
6/19/2018Peel HuntReiterated RatingBuy
5/31/2018Peel HuntReiterated RatingBuy
5/9/2018Jefferies Financial GroupReiterated RatingBuyGBX 245
5/9/2018Peel HuntReiterated RatingBuyGBX 313
4/16/2018Liberum CapitalReiterated RatingBuyGBX 248
4/4/2018Peel HuntReiterated RatingBuy
3/13/2018Liberum CapitalReiterated RatingBuyGBX 248
3/2/2018N+1 SingerReiterated RatingBuy
3/1/2018Peel HuntReiterated RatingBuyGBX 313
3/1/2018Liberum CapitalReiterated RatingBuyGBX 248
2/20/2018Peel HuntReiterated RatingBuyGBX 313
2/20/2018Numis SecuritiesReiterated RatingBuyGBX 259
2/1/2018Peel HuntReiterated RatingBuyGBX 313
1/29/2018Numis SecuritiesReiterated RatingBuyGBX 259
1/26/2018Peel HuntBoost Price TargetBuyGBX 302 ➝ GBX 313
1/26/2018Liberum CapitalReiterated RatingBuyGBX 248
1/2/2018Peel HuntReiterated RatingBuyGBX 302
12/19/2017Peel HuntReiterated RatingBuyGBX 302
11/30/2017Numis SecuritiesBoost Price TargetBuyGBX 207 ➝ GBX 233
11/30/2017Liberum CapitalReiterated RatingBuyGBX 248
11/30/2017N+1 SingerReiterated RatingBuy
11/30/2017Peel HuntReiterated RatingBuyGBX 278
11/20/2017Peel HuntReiterated RatingBuyGBX 278
11/17/2017Jefferies Financial GroupReiterated RatingBuy
11/6/2017Peel HuntReiterated RatingBuyGBX 278
10/31/2017Peel HuntReiterated RatingBuyGBX 278
9/25/2017N+1 SingerReiterated RatingBuy
9/25/2017Numis SecuritiesReiterated RatingBuyGBX 207
9/25/2017Liberum CapitalReiterated RatingBuyGBX 248
9/25/2017Peel HuntReiterated RatingBuyGBX 259
8/30/2017Jefferies Financial GroupReiterated RatingBuyGBX 225
8/30/2017Numis SecuritiesReiterated RatingBuyGBX 246
8/30/2017Liberum CapitalReiterated RatingBuyGBX 248
8/30/2017N+1 SingerReiterated RatingBuy
7/12/2017Liberum CapitalReiterated RatingBuyGBX 248
6/9/2017Jefferies Financial GroupReiterated RatingBuyGBX 255
5/16/2017N+1 SingerReiterated RatingBuyGBX 256
5/10/2017Peel HuntReiterated RatingBuyGBX 259
5/10/2017Liberum CapitalReiterated RatingBuyGBX 248
4/6/2017N+1 SingerReiterated RatingBuy
4/6/2017Jefferies Financial GroupReiterated RatingBuyGBX 255
4/6/2017Peel HuntReiterated RatingBuyGBX 259
4/6/2017Liberum CapitalReiterated RatingBuyGBX 248
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 220 ➝ GBX 246
3/24/2017Numis SecuritiesReiterated RatingBuyGBX 220
3/24/2017Peel HuntReiterated RatingBuyGBX 259
3/24/2017Liberum CapitalReiterated RatingBuyGBX 248
2/24/2017Peel HuntBoost Price TargetBuyGBX 238 ➝ GBX 259
1/5/2017Jefferies Financial GroupReiterated RatingBuyGBX 255
12/21/2016Numis SecuritiesReiterated RatingBuyGBX 220
12/21/2016N+1 SingerReiterated RatingBuyGBX 243
12/21/2016Liberum CapitalReiterated RatingBuyGBX 248
12/21/2016Peel HuntReiterated RatingBuyGBX 238
12/21/2016Jefferies Financial GroupReiterated RatingBuyGBX 255
12/15/2016Numis SecuritiesReiterated RatingBuyGBX 220
12/15/2016Liberum CapitalBoost Price TargetBuyGBX 196 ➝ GBX 248
12/12/2016Jefferies Financial GroupReiterated RatingBuyGBX 255
12/12/2016Peel HuntReiterated RatingBuyGBX 255
11/4/2016Liberum CapitalReiterated RatingBuyGBX 196
11/2/2016Peel HuntReiterated RatingBuyGBX 238
10/20/2016Numis SecuritiesBoost Price TargetBuyGBX 206 ➝ GBX 220
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PureTech Health logo
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: GBX 356
Low: 345
High: 360.90

50 Day Range

MA: GBX 336.13
Low: 321
High: 356

52 Week Range

Now: GBX 356
Low: 232.01
High: 447.66

Volume

798,383 shs

Average Volume

200,687 shs

Market Capitalization

£1.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PureTech Health?

The following Wall Street sell-side analysts have issued research reports on PureTech Health in the last year: Jefferies Financial Group Inc., Liberum Capital, Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for PRTC.

What is the current price target for PureTech Health?

4 Wall Street analysts have set twelve-month price targets for PureTech Health in the last year. Their average twelve-month price target is GBX 718.75, suggesting a possible upside of 101.9%. Peel Hunt has the highest price target set, predicting PRTC will reach GBX 930 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of GBX 475 for PureTech Health in the next year.
View the latest price targets for PRTC.

What is the current consensus analyst rating for PureTech Health?

PureTech Health currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTC will outperform the market and that investors should add to their positions of PureTech Health.
View the latest ratings for PRTC.

What other companies compete with PureTech Health?

How do I contact PureTech Health's investor relations team?

PureTech Health's physical mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company's listed phone number is +1-617-4822333. The official website for PureTech Health is puretechhealth.com.